A fine coal circuitry study using column flotation and gravity separation. Quarterly report, 1 March 1995--31 May 1995

Column flotation provides excellent recovery of ultrafine coal while producing low ash content concentrates. However, column flotation is not efficient for treating fine coal containing significant amounts of mixed-phase particles. Fortunately, enhanced gravity separation has proved to have the ability to treat the mixed-phased particles more effectively. A disadvantage of gravity separation is that ultrafine clay particles are not easily rejected. Thus, a combination of these two technologies may provide a circuit that maximizes both the ash and sulfur rejection that can be achieved by physical coal cleaning while maintaining a high energy recovery. This project is studying the potential of using different combinations of gravity separators, i.e., a Floatex hydrosizer and a Falcon Concentrator, and a proven flotation column, which will be selected based on previous studies by the principle investigator. During this reporting period, an extensive separation performance comparison between a pilot-scale Floatex Density Separator (18{times}18-inch) and an existing spiral circuit has been conducted at Kerf-McGee Coal Preparation plan for the treatment of nominally {minus}16 mesh coal. The results indicate that the Floatex is a more efficient separation device (E{sub p}=0.12) than a conventional coal spiral (E{sub p}=0.18) for Illinois seam coals. In addition, the treatment of {minus}100 mesh Illinois No. 5 fine coal from the same plant using Falcon concentrator, column flotation (Packed-Column) and their different combinations was also evaluated. For a single operation, both Falcon concentrator and column flotation can produce a clean coal product with 90% combustible recovery and 5% ash content. In the case of the combined circuit, column flotation followed by the Falcon achieved a higher combustible recovery value (about 75%) than that obtained by the individual units while maintaining an ash content less than 3%